Empagliflozin confers reno‐protection in acute myocardial infarction and type 2 diabetes mellitus
Abstract Aims Although the reno‐protective effects of sodium–glucose cotransporter 2 inhibitors are known in patients with heart failure or type 2 diabetes mellitus (T2DM), this effect has not been confirmed in patients with acute myocardial infarction (AMI). Methods and results The prospective, mul...
Main Authors: | Kosuke Mozawa, Yoshiaki Kubota, Yu Hoshika, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yu‐ki Iwasaki, Takeshi Yamamoto, Hitoshi Takano, Yayoi Tsukada, Kuniya Asai, Masaaki Miyamoto, Yasushi Miyauchi, Eitaro Kodani, Mitsunori Maruyama, Jun Tanabe, Wataru Shimizu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-10-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.13509 |
Similar Items
-
Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial
by: Wataru Shimizu, et al.
Published: (2020-09-01) -
Euglycemic Diabetic Ketoacidosis after a Single Dose of Empagliflozin in a Patient with Pancreatitis
by: Marta Brandão Calçada, et al.
Published: (2021-04-01) -
Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: A case report
by: Chie Kitahara, et al.
Published: (2021-04-01) -
Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure
by: Nikole J. Byrne, BSc, et al.
Published: (2017-08-01) -
Empagliflozin Contributes to Polyuria via Regulation of Sodium Transporters and Water Channels in Diabetic Rat Kidneys
by: Sungjin Chung, et al.
Published: (2019-03-01)